EUVIMEDEUVIMED entdecken
Open Access

Reversing Bladder Cancer Chemo-resistance through Blocking Cell Senescence by a Combination Therapy

Yirui He, Zaixiang Fang, Jiapeng Zhang, Qiang Wei, Yunkun Li, Zhenyu Duan, Gang Xu, Tianhai Lin, Qiao Xiong, Qiyong Gong, Pin Tan, Kui Luo

Theranostics · 11.05.2026 · 16 (12) · 6827-6842

DOI: 10.7150/thno.133484 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Theranostics, erschienen am 11.05.2026. Verfasst von Yirui He und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Department of Radiology, Institution of Radiology and Medical Imaging, Huaxi MR Research Center (HMRRC), Department of Hematol…. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Drug Resistance, Neoplasm, Cellular Senescence, Paclitaxel. Die Arbeit wurde bisher 6-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Rationale

Chemoresistance severely limits therapeutic options for advanced bladder cancer. Histone deacetylases (HDACs) have been implicated in tumour progression and treatment resistance, yet their role in acquired chemoresistance remains incompletely defined. We investigated whether epigenetic modulation could restore chemotherapy sensitivity in drug-refractory bladder cancer.

Methods

Expression of HDAC1-3 was analysed in tumour tissues and correlated with clinical outcomes and chemoresistance-associated transcriptional programmes. A co-delivery therapeutic strategy combining the pan-HDAC inhibitor belinostat (PXD101) with paclitaxel (PTX) was developed and evaluated in patient-derived cisplatin-resistant organoids and a platinum-refractory patient-derived xenograft (PDX) model. Functional assays and genetic perturbation experiments were performed to delineate the underlying mechanisms.

Results

HDAC1-3 were upregulated in bladder cancer tissues and associated with adverse prognosis and chemoresistance signatures. Combined PXD101 and PTX treatment significantly suppressed tumour growth in organoids and PDX models, with improved tolerability compared with standard regimens. Mechanistically, PXD101 attenuated senescence-associated programmes and reduced CDKN1A/p21 expression, thereby restoring PTX-induced antimitotic activity. Genetic manipulation identified p21 as a molecular switch linking therapy-induced senescence to chemoresistance. Modulation of p21 influenced cell-cycle re-entry, senescence burden, and responsiveness to PTX.

Conclusions

These findings define an HDAC-p21-senescence axis that sustains chemoresistance in bladder cancer and provide preclinical evidence supporting combined epigenetic and antimitotic therapy as a strategy to overcome acquired drug tolerance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Urinary Bladder NeoplasmsDrug Resistance, NeoplasmCellular SenescencePaclitaxelSulfonamidesAntineoplastic Combined Chemotherapy ProtocolsHumansAnimalsHistone Deacetylase InhibitorsHydroxamic AcidsMiceCell Line, TumorXenograft Model Antitumor AssaysCyclin-Dependent Kinase Inhibitor p21Antineoplastic AgentsFemaleCisplatinHistone Deacetylases

Stichwörter der Autor:innen

bladder cancercell senescencecombination therapydrug resistancestimulation-responsive nanomedicine

Substanzen

PaclitaxelHistone Deacetylase InhibitorsSulfonamidesbelinostatHydroxamic AcidsCyclin-Dependent Kinase Inhibitor p21Antineoplastic AgentsCisplatinHistone Deacetylases

Autor:innen und Institutionen

  • Department of Urology, Department of Radiology, Institution of Radiology and Medical Imaging, Huaxi MR Research Center (HMRRC), Department of Hematology, Frontiers Science Center for Disease-Related Molecular Network, N…
  • Psychoradiology Key Laboratory of Sichuan Province, West China Hospital, Sichuan University, Research Unit of Psychoradiology, Chinese Academy of Medical Sciences, Chengdu 610041, China.
  • Xiamen Key Lab of Psychoradiology and Neuromodulation, Department of Radiology, West China Xiamen Hospital of Sichuan University, Xiamen 361021, China.

Zitieren

APA

He, Y., Fang, Z., Zhang, J., Wei, Q., Li, Y., Duan, Z., Xu, G., Lin, T., Xiong, Q., Gong, Q., Tan, P., & Luo, K. (2026). Reversing Bladder Cancer Chemo-resistance through Blocking Cell Senescence by a Combination Therapy. Theranostics, 16(12), 6827-6842. https://doi.org/10.7150/thno.133484

Vancouver

He Y, Fang Z, Zhang J, Wei Q, Li Y, Duan Z, et al. Reversing Bladder Cancer Chemo-resistance through Blocking Cell Senescence by a Combination Therapy. Theranostics. 2026;16(12):6827-6842. doi:10.7150/thno.133484

BibTeX
@article{He2026,
  author = {He, Yirui and Fang, Zaixiang and Zhang, Jiapeng and Wei, Qiang and Li, Yunkun and Duan, Zhenyu and Xu, Gang and Lin, Tianhai and Xiong, Qiao and Gong, Qiyong and Tan, Pin and Luo, Kui},
  title = {Reversing Bladder Cancer Chemo-resistance through Blocking Cell Senescence by a Combination Therapy},
  journal = {Theranostics},
  year = {2026},
  volume = {16},
  number = {12},
  pages = {6827--6842},
  doi = {10.7150/thno.133484}
}
Kostenlos starten →